Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia | Synapse

October 13, 2015

Ver artículo completo

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL. MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Andreeff et al. (Tue,) studied this question.

synapsesocial.com/papers/69d7e4c3ec32c73b01ae339d https://doi.org/https://doi.org/10.1158/1078-0432.ccr-15-0481

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo